« Return to News | Clinical Intelligence

Altheus Therapeutics completes Zoenasa phase I trial in ulcerative colitis

Friday, June 15, 2012 11:34 AM

Altheus Therapeutics of Oklahoma City, Okla., has completed a two dose, double-blind, active-controlled phase I trial of the safety and tolerability of Zoenasa rectal suspension in adult patients with left-sided, or distal, ulcerative colitis.

"We are excited to have achieved this milestone, as it prepares Altheus to begin our planned phase II clinical program to definitively evaluate the safety and efficacy of Zoenasa in ulcerative colitis patients," said Dennis Schafer, president and CEO of Altheus.

Front-line treatment for ulcerative colitis, which affects nearly 1.2 million Americans, is monotherapy with oral or rectal mesalamine. However many patients do not achieve remission and must escalate to more expensive and risky treatments. Zoenasa is a novel combination of two FDA-approved drugs with well-established efficacy and safety records that have been shown to act synergistically for the treatment of ulcerative colitis. No serious adverse events were experienced by patients in this study.

The FDA has granted Zoenasa orphan designation for the treatment of pediatric ulcerative colitis. An oral formulation of Zoenasa is in pre-clinical development.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.